


# ACTION ON NCDs




DISCOVER HOW THE INNOVATIVE PHARMACEUTICAL INDUSTRY IS EMBRACING PARTNERSHIPS TO ACCELERATE ACTION ON NCDs

## OUR DIVERSE PARTNERS

FOR GLOBAL ACTION ON NCDs, WE COLLABORATE WITH DIVERSE PARTNERS, LEVERAGING THE STRENGTHS OF EACH PLAYER AND DEVELOPING TAILORED SOLUTIONS THAT REFLECT EACH COUNTRY'S HEALTHCARE NEEDS IN THE FIGHT AGAINST NCDs.




## TAKING ACTION TO LEAVE NO ONE BEHIND



## USING DIVERSE APPROACHES TO IMPROVE HEALTH


WE WORK BEYOND R&D INNOVATION TO CLOSE THE NCDs CARE GAP IN COUNTRIES THROUGH HOLISTIC PROGRAMMING AND ACROSS PROGRAM STRATEGIES, INCLUDING:



## A GLOBAL REACH, WITH A FOCUS ON LMICs




## CONTRIBUTING TO THE SDGs



## INNOVATING TO IMPROVE LIVES EVERYWHERE

NUMBER OF CLINICAL TRIALS FUNDED BY INDUSTRY BY DISEASE



Source for the above charts: WHO Fact Sheet on NCDs: <https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases>

Inclusion criteria involve 1) recruitment status – clinical trials that are either not yet recruiting, recruiting/enrolling by invitation, active but not recruiting and temporarily suspended; 2) study phase – including the clustering of Early Phase 1 and Phase 1; Phase 1/2 and Phase 2; Phase 2/3 and Phase 3; and Phase 4; 3) the Funder type – including IFPMA members through manual selection; and industry members.

[ifpma.org](http://ifpma.org)



[globalhealthprogress.org](http://globalhealthprogress.org)



Global Health Progress is an interactive knowledge hub highlighting over 300 active and completed collaborations between the innovative pharmaceutical industry and multi-sectoral partners focused on accelerating action on NCDs, UHC, and other health and development global goals.

